Radius Appoints Al Medwar as Senior Vice President of Business and Corporate Development

Boston, Mass., July 26, 2023 – Radius Health, Inc. (“Radius” or the “Company”), Radius Health (“Radius”), a specialty biopharmaceutical company dedicated to bone health and expanding access for patients, announced the appointment of Al Medwar to the role of Senior Vice President of Business and Corporate Development, reporting to the Company’s Chief Executive Officer, Scott Briggs.

“Radius is dedicated to building a portfolio of products to address important and unmet medical needs of patients including those related to bone health,” said Mr. Briggs. “I am very pleased by the addition of Al to the executive team, as his experience and past successes in business and corporate development will be vital to the future growth of Radius.”

Mr. Medwar, an accomplished pharmaceutical executive with over thirty years of pharmaceutical industry experience, will lead business and strategy development in efforts to expand the Radius product portfolio and build upon the growth of TYMLOS® for osteoporosis. Mr. Medwar brings significant business development experience which includes numerous in and out-licensing transactions to support growth-oriented commercial stage and biotech companies.

“I am excited to join Radius at such a dynamic time and look forward to working very closely with Scott, the leadership team, and our investors to identify meaningful growth opportunities to both broaden our product portfolio and address unmet medical needs of patients in bone health and related areas,” said Mr. Medwar.

Prior to joining Radius, Mr. Medwar most recently served as Senior Vice President of Investor Relations and Corporate Communications and a member of the executive team at 9 Meters Biopharma, Inc., where he was responsible for investor and public relations and played a significant role in supporting strategic and business development efforts. Mr. Medwar also previously served as Executive Vice President of Corporate and Business Development at BioDelivery Sciences where he played an integral role over twelve years in numerous successful business development and financing transactions through the transition of the company from a development stage to a commercial entity with multiple marketed products. Mr. Medwar began his career in sales and marketing for Glaxo Wellcome. He received a BA from Cornell University and his MBA from Bentley University Graduate School of Business.

About Radius
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 for the treatment of men with osteoporosis at high risk for fracture.

Contact:
Sara Goldberg: Lead, Communications
Email: [email protected]
Phone: +1 (631) 379-8374